CN103073440B - Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof - Google Patents
Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof Download PDFInfo
- Publication number
- CN103073440B CN103073440B CN201310054592.0A CN201310054592A CN103073440B CN 103073440 B CN103073440 B CN 103073440B CN 201310054592 A CN201310054592 A CN 201310054592A CN 103073440 B CN103073440 B CN 103073440B
- Authority
- CN
- China
- Prior art keywords
- acid
- reaction
- toluylene
- compound
- alkali metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C1)=CC(*)=C[C@@]1C=Cc(cc1)ccc1OC* Chemical compound CC(C1)=CC(*)=C[C@@]1C=Cc(cc1)ccc1OC* 0.000 description 1
- MDUTXYLPODCITG-OWOJBTEDSA-N Nc1ccc(/C=C/c2cc(O)cc(O)c2)cc1 Chemical compound Nc1ccc(/C=C/c2cc(O)cc(O)c2)cc1 MDUTXYLPODCITG-OWOJBTEDSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a novel diphenylvinyloxy alkylamine compound (I) and a pharmaceutically acceptable salt thereof, and a preparation method as well as application thereof to preparation of medicaments for treating and/or preventing neurodegenerative related diseases, including but not limited to neurodegenerative diseases such as vascular dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, HIV (Human Immunodeficiency Virus) related dementia, multiple sclerosis, progressive lateral sclerosis, neuropathic pain and glaucoma. In a formula (I), Ar represents any structural unit from (A) to (D) shown in the specification, and n is equal to 1, 2.
Description
Technical field
The invention belongs to medicinal chemistry art, relate to the novel toluylene oxyalkyl amine based compound of a class (
i) and pharmacy acceptable salt, its preparation method and preparing the purposes that treats and/or prevents in nervus retrogression relative disease medicine, include but not limited to the nerve degenerative diseases such as vascular dementia, Alzheimer's disease, parkinsonism, huntington disease, HIV related dementia disorders, multiple sclerosis, progressive lateral sclerosis disease, neuropathic pain, glaucoma.
Background technology
Vascular dementia (Vascular Dementia, VD) be the clinical syndrome of intelligence caused by various types of cerebrovascular disease (comprising ischemic cerebrovascular disease, hemorrhagic cerebrovascular disease, acute and hypoxia-induced cerebrovascular disease etc.) and cognition dysfunction, its main clinical manifestation comprises: cognitive ability, memory and social-life ability go down and emotion, personality change, be a kind of chronic progressive disease.In first reason that Asian countries's vascular dementia such as Chinese, Japanese is senile dementia; Along with world population is to the continuous propelling of aging, cerebro-vascular diseases is increasing, and Onset of Vascular Dementia rate has the trend risen gradually, has a strong impact on work and the quality of life of the elderly, and brings heavy economy and mental burden to society and family.Therefore, VD to have become in current geriatrics and psychologic medicine field an important study hotspot.Vascular dementia is complicated due to pathogenesis, there is no the medicine that can block disease progression, and current clinical treatment is to improve brain blood circulation and brain metabolism, and it is main for strengthening brain nutrition.
In recent years, research both at home and abroad shows, the also frequent exception with cholinergic system while VD patients cerebral damage.VD patient's hippocampus ChAT positive neuron and fibre density lower, the ChAT activity decrease of different sites in brain, and the ACh concentration in VD Cerebrospinal Fluid in Patients is starkly lower than normal level, and the degree that its concentration reduces is proportionate with dull-witted severity; And cerebral ischemia can cause acetylcholine esterase active in brain to rise; Simultaneously also to find that some acetylcholinesterase depressant are as the neuronal damage that HuperzineA and Revastigmine can protect ischemic to cause; and the recovery of nerve injury and brain function after cerebral ischemia can be promoted, show that acetylcholinesterase depressant can be used for the treatment of vascular dementia.
Alzheimer's disease (Alzheimer ' s disease, AD) be a kind of central nervous system degenerative disease damaged based on Progressive symmetric erythrokeratodermia cognitive disorder and memory, its sickness rate is in ascendant trend year by year, become the frequently-occurring disease being only second to cardiovascular diseases and cancer, rise to the 4th of the cause of death in developed countries such as America and Europes.According to WHO Report, global over-65s old man has 10% dysnoesia, and wherein 1/2nd dementia occur, more than 85 years old sickness rate nearly 50%.At present, China AD number of patients is more than 5,000,000, and this disease there is no effective treatment means at present, and along with the quickening of China's aging population process, this numeral will be more huge.Because AD clinical manifestation is that memory capability, orientation property, thinking and judgement go down, and activity of daily living reduces, even there is abnormal Behavioral and psychological symptom etc., make patient care difficulty larger, bring heavy burden to society and family, thus, novel senile dementia medicine is researched and developed significant.From the market requirement, " senile dementia report " prediction that world market research and strategist company complete recently, the global marketing volume to senile dementia medicine in 2015 will reach 10,000,000,000 dollars; In China, along with the rapid rising of senile dementia sickness rate, the market also rapid expansion of this kind of medicine.
AD belongs to the disease that many factors causes, pathogeny is complicated, so far also its pathogenesis is not illustrated completely, dissect after death and find cerebral amyloid sample senile plaque (Senile Plaques, SP) and neurofibrillary tangles (Neurofibrillary Tangles, NFT) be the histopathologic change of patient's AD most feature.In recent years, many investigators are devoted to from molecule and cell levels to disclose the pathogeny of AD, propose multiple hypothesis, as: the deposition, Protein tau Hyperphosphorylationof, inflammation, free-radical oxidn, metal ion imbalance etc. of cholinergic neuron damage, amyloid, therefore, the novel therapeutic approach developed for these pathogenesis and means, will be hopeful the state of an illness alleviating and improve AD patient.The medicine of effectively treating AD at present clinically mainly contains two classes: the cholinergic hypothesis that (1) causes cognitive function to be lacked of proper care based on neurotransmitter acetic acid choline deficiency, acetylcholinesterase depressant is adopted to improve second phthalein choline levels in patient's brain, as: Tacrine, Donepezil, Ravastigmine, Galantamine; (2) adopt
n-methyl-D-asparagic acid (NMDA) acceptor inhibitor reduces glutaminate to the damage of neurocyte, as: Memantine Hydrochloride.But these medicines exist, and action target spot is single, toxic side effect is more, to the problem such as the long-term efficacy of AD patient is not good enough.Therefore, research and development have novel chemical structure, novel mechanism of action, multiaction target spot, low toxic side effect anti-neurodegenerative disease therapeutic agent not only meet the active demand of social senilization's process, and there are good market outlook.
Summary of the invention
The object of the invention be to disclose a class toluylene oxyalkyl amine based compound (
i) and pharmacy acceptable salt.
Another object of the present invention be to disclose such toluylene oxyalkyl amine based compound (
i) and the preparation method of pharmacy acceptable salt.
Still a further object of the present invention be to disclose such toluylene oxyalkyl amine based compound (
i) and pharmacy acceptable salt preparing the purposes that treats and/or prevents in nervus retrogression relative disease medicine, include but not limited to the nerve degenerative diseases such as vascular dementia, Alzheimer, parkinsonism, huntington disease, HIV related dementia disorders, multiple sclerosis, progressive lateral sclerosis disease, neuropathic pain, glaucoma.
Toluylene oxyalkyl amine based compound disclosed in this invention (
i) chemical structure of general formula be:
In formula:
arbe expressed as follows shown
(A)~
(D)middle any structural unit, n=1,2;
R
1represent H, C
1~ C
12alkyl; R
2represent C
1~ C
12alkyl, benzyl, substituted benzyl, 1,2,3,4-tetrahydro acridine-9-base, chloro-1,2,3, the 4-tetrahydro acridine-9-base of 6-, chloro-1,2,3, the 4-tetrahydro acridine-9-base of 8-or chloro-1,2,3, the 4-tetrahydro acridine-9-base of 6,8-bis-; R
1nR
2also represent Pyrrolidine base, morpholinyl,
n-demethylgalanthamine base, piperidyl, 4-position are by C
1~ C
12the piperidyl that alkyl replaces, 4-position by benzyl or substituted benzyl replace piperidyl, piperazinyl, 4-position is by C
1~ C
12the piperazinyl that alkyl replaces, 4-position by benzyl or substituted benzyl the piperazinyl that replaces; R
3represent H, C
1~ C
12alkyl;
linkerrepresent (CH
2)
m, m represents 1-12; "
-O-Linker-NR 1 r 2 " also can be
, m represents 1-12, R
5represent H, C
1~ C
12alkyl, benzyl or substituted benzyl; Wherein, when Ar represent (
a) structural unit and R
3represent CH
3,
linkerfor (CH
2)
m, when m is 2 or 3,
r 1 nR 2 do not represent dimethylin, diethylin, morpholinyl, piperazinyl, 4-methylpiperazine base, Pyrrolidine base or piperidyl.
Above-mentioned term " substituted benzyl " refer to by phenyl ring by 1-4 to be selected from the group of lower group the benzyl that replaces: F, Cl, Br, I, C
1-4alkyl, C
1-4alkoxyl group, trifluoromethyl, trifluoromethoxy, nitro, cyano group, these substituting groups can at any possible position of phenyl ring.
Toluylene oxyalkyl amine based compound proposed by the invention (
i) prepare by following methods:
(1) when Linker represents (CH
2
)
m
, Ar represents structural unit (A) or (B), and R
3
when not representing structural unit (C) and (D) of H:
In formula:
xrepresent Cl, Br, I; Ar, R
1, R
2, the definition of m, n and chemical structure of general formula (
i) identical.
With corresponding toluylene phenolic compound (
1) be starting raw material, in the basic conditions with Dihaloalkyl compound (
2) reaction, generate corresponding toluylene oxyalkyl halogen compound (
3), gained intermediate
3with organic amine compound (
4) reaction, obtain corresponding toluylene oxyalkyl amine based compound (
i);
Its concrete preparation method is described below:
Described step
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, trimethylamine class or quaternary ammonium bases (as: triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine, TBAH), preferred bases is: potassium hydroxide, sodium hydroxide, salt of wormwood, triethylamine, pyridine or sodium methylate; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF) or toluene; Toluylene phenolic compound (
1): Dihaloalkyl compound (
2): the molar feed ratio of alkali is 1.0:1.0 ~ 15.0:1.0 ~ 15.0, and preferred molar feed ratio is 1.0:1.0 ~ 6.0:1.0 ~ 6.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred reaction time is 2 ~ 24 hours.
Described step
b)in, reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile, C
1-8alcohol or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF), ethanol or toluene; Compound (
3): organic amine compound (
4) molar feed ratio be 1.0:1.0 ~ 15.0, preferred molar feed ratio is 1.0:1.0 ~ 6.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred reaction time is 2 ~ 24 hours.
(2) when Linker represents (CH
2
)
m
, Ar is R
3
when the structural unit (C) of=H or (D):
In formula:
xrepresent Cl, Br, I; Ar, R
1, R
2, the definition of m and chemical structure of general formula (
i) identical.
With trans-resveratrol (
1) be starting raw material, react with chloromethyl methyl ether under solvent and alkaline condition, generate corresponding methoxy methylene radical protection trans-resveratrol (
5) or (
6), gained intermediate (
5) or (
6) under solvent and alkaline condition with Dihaloalkyl compound (
2) reaction, generate corresponding fragrant oxygen dialkyl group halogen compound (
7), this intermediate
7with organic amine compound (
4) react in a solvent, obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
8), compound
8under solvent and acidic conditions, remove methoxy methylene radical protecting group, obtain corresponding trans-resveratrol dialkylamine compounds (
i);
Its concrete preparation method is described below:
Described step
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates or C
1-8an alkali metal salt of alcohol, preferred bases is: potassium hydroxide, sodium hydroxide, salt of wormwood or sodium methylate; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF) or toluene; Trans-resveratrol (
1): chloromethyl methyl ether: the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 5.0, and preferred molar feed ratio is 1.0:1.0 ~ 5.0:1.0 ~ 3.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable temperature is room temperature ~ 120 DEG C; Reaction times is 0.5 ~ 24 hour, and the preferred time is 1 ~ 12 hour.
Described step
b)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, trimethylamine class or quaternary ammonium bases (as: triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine, TBAH), preferred bases is: potassium hydroxide, sodium hydroxide, salt of wormwood, triethylamine, pyridine or sodium methylate; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF) or toluene; Intermediate (
5) or (
6): Dihaloalkyl compound (
2): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0, and preferred molar feed ratio is 1.0:1.0 ~ 5.0:1.0 ~ 5.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred reaction time is 2 ~ 24 hours.
Described step
c)in, reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile, C
1-8alcohol or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF), ethanol or toluene; Intermediate (
7): organic amine compound (
4) molar feed ratio be 1.0:1.0 ~ 10.0, preferred molar feed ratio is 1.0:1.0 ~ 5.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred reaction time is 2 ~ 24 hours.
Described step
d)in, reaction solvent for use is: water, C
1-6fatty alcohol,
n,N-dimethyl formamide, tetrahydrofuran (THF), C
3-8aliphatic ketone, acetonitrile, Isosorbide-5-Nitrae-dioxane or dimethyl sulfoxide (DMSO), preferred solvent is: water, methyl alcohol, ethanol, Isosorbide-5-Nitrae-dioxane or acetone; Acid used is: hydrogenchloride, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phenylformic acid, C
1-6lipid acid, C
1-6alkylsulphonic acid, Phenylsulfonic acid, tosic acid or trifluoroacetic acid, preferred acid is: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, methanesulfonic, tosic acid or trifluoroacetic acid; The massfraction of acid in reaction system is 0.1%-100%, and preferred mass mark is 10%-95%, and temperature of reaction is 0 ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 30 minutes ~ 24 hours, and the preferred reaction time is 1 ~ 8 hour.
(3) when
represent
, Ar represents structural unit (A) or (B), and R
3
when not representing structural unit (C) and (D) of H:
In formula: X represents Cl, Br, I; Ar, R
5, the definition of m, n and chemical structure of general formula (
i) identical.
With corresponding toluylene phenolic compound (
1) be starting raw material, replace with 1-in the basic conditions-4-alkylhalide group piperazine (
9) reaction, obtain corresponding toluylene oxyalkyl amine based compound (
i);
Its concrete preparation method is described below:
Reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, trimethylamine class or quaternary ammonium bases (as: triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine, TBAH) or C
1-8an alkali metal salt of alcohol, preferred bases is: potassium hydroxide, sodium hydroxide, salt of wormwood, triethylamine, pyridine or sodium methylate; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF) or toluene; Toluylene phenolic compound (
1): 1-replacement-4-alkylhalide group piperazine (
9): the molar feed ratio of alkali is 1.0:1.0 ~ 15.0:1.0 ~ 15.0, and preferred molar feed ratio is 1.0:1.0 ~ 6.0:1.0 ~ 6.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred reaction time is 2 ~ 24 hours.
(4) when
represent
, Ar is R
3
when the structural unit (C) of=H or (D):
In formula: X represents Cl, Br, I; Ar, R
5, the definition of m and chemical structure of general formula (
i) identical.
With methoxy methylene radical protection trans-resveratrol (
5) or (
6) be starting raw material, replace with 1-under solvent and alkaline condition-4-alkylhalide group piperazine (
9) reaction, obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
10), compound
10under solvent and acidic conditions, remove methoxy methylene radical protecting group, obtain corresponding trans-resveratrol dialkylamine compounds (
i);
Its concrete preparation method is described below:
Described step
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, trimethylamine class or quaternary ammonium bases (as: triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine, TBAH), preferred bases is: potassium hydroxide, sodium hydroxide, salt of wormwood, triethylamine, pyridine or sodium methylate; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane, preferred solvent is:
n,N-dimethyl formamide, acetone, acetonitrile, tetrahydrofuran (THF) or toluene; Methoxy methylene radical protection trans-resveratrol (
5) or (
6): 1-replacement-4-alkylhalide group piperazine (
9): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0, and preferred molar feed ratio is 1.0:1.0 ~ 5.0:1.0 ~ 5.0; Temperature of reaction is room temperature ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 1 ~ 72 hour, and the preferred time is 2 ~ 24 hours.
Described step
b)in, reaction solvent for use is: water, C
1-6fatty alcohol,
n,N-dimethyl formamide, tetrahydrofuran (THF), C
3-8aliphatic ketone, acetonitrile, Isosorbide-5-Nitrae-dioxane or dimethyl sulfoxide (DMSO), preferred solvent is: water, methyl alcohol, ethanol, Isosorbide-5-Nitrae-dioxane or acetone; Acid used is: hydrogenchloride, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phenylformic acid, C
1-6lipid acid, C
1-6alkylsulphonic acid, Phenylsulfonic acid, tosic acid or trifluoroacetic acid, preferred acid is: hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, methanesulfonic, tosic acid or trifluoroacetic acid; The massfraction of acid in reaction system is 0.1%-100%, and preferred mass mark is 10%-95%, and temperature of reaction is 0 ~ 150 DEG C, and preferable reaction temperature is room temperature ~ 120 DEG C; Reaction times is 30 minutes ~ 24 hours, and the preferred reaction time is 1 ~ 8 hour.
According to above-mentioned four kinds of method gained toluylene oxyalkyl amine based compound (
i) in molecule containing amino, this amino is in alkalescence, and can obtain acceptable salt on its pharmacology with any suitable acid by the salifying method of pharmaceutically routine, described acid is: hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid, C
1-6aliphatic carboxylic acid (as: formic acid, acetic acid, propionic acid etc.), oxalic acid, phenylformic acid, Whitfield's ointment, toxilic acid, fumaric acid, succsinic acid, tartrate, citric acid, C
1-6alkylsulphonic acid (as: methylsulphonic acid, ethylsulfonic acid etc.), camphorsulfonic acid, Phenylsulfonic acid or tosic acid.
Toluylene oxyalkyl amine based compound disclosed in this invention (
i) and pharmacy acceptable salt measure its purity through HPLC, show the equal >98.5% of its content, following bioactivity screening carried out to these compounds.
(1) acetylcholinesterase and butyrylcholine esterase inhibit activities
1.0mmol/L acetylthiocholine iodide or sulfur iodide is added successively for BuCh (equal available from Sigma) 30 μ L in 96 orifice plates, the PBS damping fluid 40 μ L of pH7.4, testing compound solution 20 μ L(DMSO content is less than 1%) and 10 μ L acetylcholinesterases (rat brain cortex 5% homogenate supernatant liquor, the phosphoric acid buffer of pH7.4 makes homogenate medium) or butyrylcholine esterase (rat blood serum 25% supernatant liquor, pH7.4 phosphoric acid buffer makes homogenate medium) solution, after finishing mixing, hatch 15min for 37 DEG C, 0.2% 5 are added in each hole, 5 '-dithio-bis-(2-nitrobenzoic acid) (DTNB, available from Sigma) solution 30 μ L develops the color, the optical density(OD) (OD value) in each hole, 405nm place is measured by microplate reader, compare with the blank well not adding testing sample, computerized compound is to the inhibiting rate (enzyme inhibition rate (%)=(1-sample sets OD value/blank group OD value) × 100%) of enzyme, select five to six concentration of compound, measure its enzyme inhibition rate, and with the inhibiting rate linear regression of the negative logarithm of this compound volumetric molar concentration and enzyme, volumetric molar concentration when trying to achieve 50% inhibiting rate is the IC of this compound
50.Measurement result shows, compound disclosed in this invention all has remarkable restraining effect to acetylcholinesterase, its IC
50be 1.0 nM ~ 10.0 μM, and positive control medicine---Rivastigmine is to the IC of acetylcholine ester enzyme level
50it is 6.3 μMs; Measurement result also shows, the inhibit activities of compound disclosed in this invention to acetylcholinesterase is much higher than the inhibit activities to butyrylcholine esterase, illustrates that compound disclosed in this invention has certain selective inhibitory to acetylcholinesterase.
(2) compound is to H
2
o
2
the provide protection screening of the PC12 cell injury of induction
The DMEM nutrient solution of PC12 cell containing 10 % calf serums, with 1 × 10
5individual/mL density is inoculated on 96 well culture plates, and inoculation volume is 100 μ L/ holes, puts into subsequently containing 5% CO
237 DEG C of constant incubators in cultivate.Cultivate after 24 hours, (final concentration is 10 to add the compound of respective concentration in administration group
-5mol/L, 10
-6mol/L) 10 μ L/ holes, 2 hours (control group and damage group add 10 μ L/ hole PBS respectively, make its volume keep equal) of preincubate.PC12 cell incubation, after 2 hours, adds 100 μMs of H respectively in administration group and damage group
2o
2damage agent 10 μ L/ hole (control group adds 10 μ L/ hole PBS), after 30 minutes, the RPMI RPMI-1640 all changed into by the nutrient solution of each group without calf serum continues to put into constant incubator cultivation 24 hours, and nutrient solution volume is still 100 μ L/ holes.Continue cultivation after 24 hours, add 5 mg/mL MTT 100 μ L/ holes in each group, carry out viable cell dyeing.After 3 hours, 100% DMSO stop buffer 100 μ L/ hole is added in each group, abundant dissolving mixing, the OD value of each group is measured under the wavelength of 490 nm, test result repeats 3 times, and with Duncan ' s test method statistic, the numeric representation of each group is mean ± S.E.M., with control group for 100%, administration group and damage class value represent with the per-cent of control group.Measurement result shows, in the embodiment of the present invention, the PC12 cell injury of disclosed compound to hydrogen peroxide-induced all has significant provide protection, and 10
-5anti-oxidant activity under mol/L concentration is all better than trans-resveratrol and Pterostilene.
(3) compound is on the impact of Scopolamine induced mice memory acquisition disturbance
SPF level ICR male mice, 25-30g, is divided at random: normal group, model group, by reagent high and low dose group (5.0,2.5mg/kg), often organize 10 animals.Disposable gavage gives test medicine, and blank group and model group give solvent 0.5%CMC-Na, and administration volume is 0.1ml/10g; 45 min after medicine, normal group mouse peritoneal injecting normal saline, all the other each treated animals all inject Scopolamine (5mg/kg), and administration volume is 0.1ml/10g; After modeling 30 min, mouse is put into non-electricity irritation Y labyrinth and carry out Behavior test.Mouse is put in an arm end during test, be allowed to condition in labyrinth and freely walk 8min, record its number of times entering each arm and alternate frequency, rate is replaced: alternately rate %=[alternate frequency/(always entering number of times-2)] × 100 according to following formulae discovery, result represents with mean ± standard deviation, and group difference adopts one-way analysis of variance.Measurement result shows, under this experiment condition, compound disclosed in this invention causes to Scopolamine the improvement result that the acquired dysmnesia of mouse have dose-dependently, more all has significant difference (p<0.01) with model group.
(4) compound is on the impact of ethanol induced mice reproducibility dysmnesia
SPF level ICR male mice, 25-30g, is divided at random: normal group, model group, by reagent high and low dose group (5.0,2.5mg/kg), rivastigmine group (3mg/kg), often organize 10 animals.Every day, gavage gave test medicine, and blank group and model group give solvent 0.5%CMC-Na, and administration volume is 0.1ml/10g, successive administration 32 days; In administration during 1 ~ 24 day, 30 min after every day medicine, model group and each administration group gavage 0.1ml/10g ethanol (15% w/v), give 24 days continuously, and remove ethanol and enter ethanol and clean the phase, medicine continues to give; Within 31,32 days, animal Jumping test is carried out in administration; after medicine, 45min carries out training or test experiments; allow mouse be placed in diving tower instrument during training, put down gently on platform, energising; contact copper grid for getting an electric shock with biped when animal jumps off from platform simultaneously; be considered as wrong reaction, mouse shocked by electricity after normal avoiding reaction for escape on platform, record mouse escape to the latent period on platform; and the electric shock number of times recorded in 5min, in this, as school grade.Test after 24 hours, record mouse first time jumps off the time (latent period) and the interior number of times (errors number) shocked by electricity of 5 min thereof of being shocked by electricity, in this, as the evaluation index of memory represents function.Test result represents with mean ± standard deviation, and group difference adopts one-way analysis of variance.Measurement result shows, under this experiment condition, compound disclosed in this invention is significantly improved the equal tool of ethanol induced mice memory represents dysfunction, more all has significant difference (p<0.01) with model group.
(5) neuroprotective of compound on vascular dementia rats
(a) animal model, grouping and administration
Rats by intraperitoneal injection 3.5% chloral hydrate anesthesia (350 mg/kg), is separated bilateral carotid, ligation, sham-operation normal group not ligation bilateral common carotid arteries.The concealment Platform Screening experiment of postoperative 7 days row water maze test in 5 days, using animal latent period of the 5th day as screening index: SR=(operation group average latency-normal group average latency) equal latent period of/normal group animal.Screen neurobehavioral handicapped model success animal with SR<0.2, be divided into normal group, model group, medicine high dose group (45 mg/kg) and low dose group (15 mg/kg) at random, often organize 12; Postoperative 13rd day starts to gavage administration, and normal group and model group give equal-volume solvent; Successive administration is after 3 weeks, and row water 7 days labyrinth test experiments are to evaluate the impact of medicine on vascular dementia rats neurobehavioral function.After Behavior test, after Animal Anesthesia, sequentially use PBS(pH 7.4) and 4% paraformaldehyde solution through the quick perfusion of heart, open rapidly cranium and get brain, 10% neutral formalin fixes 24 hours, paraffin embedding, make the brain coronal section of thickness about 5 μm, for europathology histological examination.Experimental data all represents with mean ± standard deviation, and experimental result adopts SPSS16 software to carry out statistical study, and comparing between group and adopt one-way analysis of variance LSD method, take P<0.05 as significant difference.
(b) neurobehavioral functional examination
Morris water maze testing method is adopted to evaluate medicine to the impact of vascular dementia rats Spatial learning and memory ability.Water maze is a circular white stainless steel pond, diameter 120cm, high 60cm, pond is divided into 4 quadrants, places a platform at quadrant 1 center, platform and the center of circle and pool wall equidistant, platform is that white is circular, diameter 10cm, high 20cm, platform is positioned at underwater 2cm, pond water temperature remains on 25 ± 2 DEG C, adds appropriate foodstuff additive antholeucin in water, makes Chi Shui be opaque oyster white, animal does not arrive platform, to detect the acuteness of animal to locus by vision.Have a camera directly over pond, camera is connected with computer, by animal activity situation in computer record pond.After administration, water maze laboratory carries out 7 days continuously, and 1-2 days is concealment platform experiments, and record rat finds plateau time (latent period); Within 3rd day, in order to explore platform experiments (namely removing platform), rat place of entry invariant position, record rat is at residence time of place, original platform position quadrant and traversing times; Within 4-6 days, be new platform experiments (namely position of platform changes), rat place of entry invariant position, record rat finds the time (latent period) of platform; 7th day is visible platform experiments, rat place of entry invariant position, and record rat finds plateau time (latent period).Morris water maze is a kind of experiment relying on hippocampus memory function, is mainly used in the evaluation of cerebral ischemic injury Cognitive Impairment.Cognitive function generally comprises three phases: obtain, consolidate and memory, and in this experiment, concealment platform experiments detects and obtains function, and new platform experiments detects study and consolidates function, explores platform experiments and detects memory function.
Measurement result shows, obviously to shorten the latent period that rat is hiding platform and new platform with model group comparative drug treatment group, and in exploration platform experiments, and animal obviously extended in residence time of original platform quadrant and traversing times.Experimental result confirms that the pharmacological agent of compound disclosed in this invention dose-dependently obviously can improve the cognition dysfunction of the vascular dementia caused by the long-term Low perfusion of brain.In addition, visible platform experiments result shows, platform no significant difference in latent period between each group, thus gets rid of the impact of performing the operation on animal vision and motor capacity, further demonstrate that the result for the treatment of of medicine to vascular dementia.
the detection of (c) neuronal damage
Detected neuronal nuclear antigen (NeuN) expression level of VD animal brain cortex and hippocampus by ImmunohistochemistryMethods Methods, evaluate medicine to the impact of VD animal brain neuronal damage.Get every animal brain coronal paraffin slides, dimethylbenzene dewaxes, the H of 3%
2o
2after deactivating endogenous peroxydase, drip 5%BSA confining liquid, after 37 DEG C of incubators hatch 1 hour, add NeuN polyclonal antibody (1:200, Beijing Bo Aosen Bioisystech Co., Ltd) respectively, to hatch after 2 hours dislocation in 4 DEG C of refrigerator overnight for 37 DEG C.Add biotinylation sheep anti-Mouse two anti-, 37 DEG C hatch 1 hour, then add SABC, 37 DEG C hatch 1 hour after, DAB colour developing, Hematorylin are redyed.Routine is dewatered, dimethylbenzene is transparent, neutral gum mounting.Under 400 times of opticmicroscopes, blind is observed and is recorded cortex and the nonoverlapping region positive cell count of hippocampus 3, and calculate and often open section mean value, with control group for 100%, the positive cell number of model group and administration group represents with the per-cent of control group.
Measurement result shows, significantly reduces (P<0.01) with the neuronal cell quantity of the cortex of normal group comparison model group and the NeuN immuno positive of hippocampus; Compared with model group, medicine can increase neuronal cell quantity (P<0.05 or P<0.01) by dose-dependently.Experimental result shows, compound disclosed in this invention can suppress the damage of vascular dementia rats cerebral neuron cell, and the result that this and medicine can improve Morris water maze laboratory medium vessels dementia rats cognitive function conforms to.
the detection of (d) microglia activation
Get every animal brain coronal paraffin slides, dimethylbenzene dewaxes, the H of 3%
2o
2after deactivating endogenous peroxydase, drip 5%BSA confining liquid, after 37 DEG C of incubators hatch 1 hour, add OX-42 polyclonal antibody (1:200 respectively, Millipore company, USA) or GFAP polyclonal antibody (1:100, Wuhan Boster Biological Technology Co., Ltd.), dislocation is hatched after 2 hours in 4 DEG C of refrigerator overnight for 37 DEG C.Add biotinylation sheep anti-Mouse two anti-, 37 DEG C hatch 1 hour, then add SABC, 37 DEG C hatch 1 hour after, DAB colour developing, Hematorylin are redyed, and conventional dehydration, dimethylbenzene are transparent, neutral gum mounting; Figure adopted by immunohistochemical staining Axiovert 40 CFL microscope: under 400 times of opticmicroscopes, often opening section to choose 3 different zones in pallium fixed position and adopt figure, by the accumulation optical density value (IOD) of Image Pro-plus5.0 software analysis immune response positive cell, calculate and often open section IOD mean value, often organize result and represent with mean ± standard deviation.
Measurement result shows, all significantly increases (P <0.01) with OX-42 and the GFAP expression level of normal group comparison model group cortex; Medicine can reduce OX-42 and GFAP expression by dose-dependently compared with model group, and wherein high dose group has remarkable significant difference (P<0.01).Experimental result shows, compound disclosed in this invention can suppress the activation of vascular dementia rats microglia and astroglia cell, plays prevention and treatment by suppressing Neuroinflammation to vascular dementia.
Embodiment
Can be conducted further description the present invention by the following examples, but scope of the present invention is not limited to following embodiment.One of skill in the art can understand, and under the prerequisite not deviating from the spirit and scope of the present invention, can carry out various change and modification to the present invention.
embodiment 1 is worked as Linker and is represented (CH
2
)
m
, when Ar represents structural unit (A) or (B), method is led in the preparation of toluylene oxyalkyl amine based compound (I)
Add in reaction flask the corresponding toluylene phenolic compound of 5.0 mmol (
1),
n,N-dimethyl formamide 30 ml, dibromo alkylate (
2) 20.0 mmol and 5.2 mmol salt of wormwood, under argon shield, be warming up to 50-60 DEG C of stirring reaction 6.0 ~ 18.0 hours (reaction process TLC follows the tracks of); After reaction terminates, filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression steam desolventize and excessive dibromo alkylate, resistates through column chromatography purification (elutriant: chloroform-methanol=30:1 v/v), obtain corresponding toluylene oxyalkyl bromine compounds (
3).According to starting raw material toluylene phenolic compound used (
1) difference, can obtain toluylene oxyalkyl bromine compounds that corresponding 3-position or 4 '-position replace (
3); Wherein, when toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
a) time, obtain 4 '-position replace toluylene oxyalkyl bromine compounds (
3), yield 76%-93%; When toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
b) time, obtain 3-position replace toluylene oxyalkyl bromine compounds (
3), yield 70%-90%; When toluylene phenolic compound (
1) be trans-resveratrol (R
3represent H structural unit (
a) or (
b)) time, can obtain simultaneously 3-position replace toluylene oxyalkyl bromine compounds (
3) and 4 '-position replace toluylene oxyalkyl bromine compounds (
3), yield is respectively 15%-36% and 32%-48%.
Toluylene oxyalkyl bromine compounds that the above-mentioned corresponding 3-position for preparing or 4 '-position are replaced (
3) 1.0 mmol are dissolved in 15 ml ethanol, add 3.0 mmol organic amine compounds (
4), temperature rising reflux stirring reaction 3.0 ~ 12.0 hours (reaction process TLC follows the tracks of) under argon shield; After reaction terminates, remove solvent under reduced pressure, 50 ml methylene dichloride are added in resistates, use 15 ml 5% aqueous sodium carbonates and 15 ml deionized water wash successively, organic layer filters after anhydrous sodium sulfate drying, remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: dichloromethane-acetone=30:1 v/v), obtain corresponding toluylene oxyalkyl amine based compound (
i), yield 82%-95.8%, the equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
(continuous upper table)
(continuous upper table)
(continuous upper table)
(continuous upper table)
(continuous upper table)
embodiment 2 is worked as Linker and is represented (CH
2
)
m
, Ar represents R
3
when not being structural unit (C) or (D) of H, method is led in the preparation of toluylene oxyalkyl amine based compound (I)
Add in reaction flask the corresponding toluylene phenolic compound of 2.0 mmol (
1),
n,N-dimethyl formamide 30 ml, dibromo alkylate (
2) 20.0 mmol and 10.0 mmol salt of wormwood, under argon shield, be warming up to 80-85 DEG C of stirring reaction 3.0 ~ 12.0 hours (reaction process TLC follows the tracks of); After reaction terminates, filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression steam desolventize and excessive dibromo alkylate, resistates through column chromatography purification (elutriant: chloroform-methanol=50:1 v/v), obtain corresponding toluylene oxyalkyl bromine compounds (
3).Wherein, when toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
c) time, obtain 3,4 '-dibasic toluylene oxyalkyl bromine compounds (
3), yield 80%-96%; When toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
d) time, obtain 3,5-dibasic toluylene oxyalkyl bromine compounds (
3), yield 72%-88%.
Corresponding dibasic toluylene oxyalkyl bromine compounds of preparing above-mentioned (
3) 1.0 mmol are dissolved in 15 ml ethanol, add 6.0 mmol organic amine compounds (
4), temperature rising reflux stirring reaction 3.0 ~ 12.0 hours (reaction process TLC follows the tracks of) under argon shield; After reaction terminates, remove solvent under reduced pressure, 50 ml methylene dichloride are added in resistates, use 15 ml 5% aqueous sodium carbonates and 15 ml deionized water wash successively, organic layer filters after anhydrous sodium sulfate drying, remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: methylene dichloride), obtain corresponding toluylene oxyalkyl amine based compound (
i), yield 80%-97%, the equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
(continuous upper table)
(continuous upper table)
。
embodiment 3 is worked as Linker and is represented (CH
2
)
m
, Ar is R
3
when the structural unit (C) of=H or (D), method is led in the preparation of toluylene oxyalkyl amine based compound (I)
Add in reaction flask 5.0 mmol trans-resveratrols (
1),
n,N-dimethyl formamide 30 ml, chloromethyl methyl ether 8.0 mmol and 5.2 mmol salt of wormwood, be warming up to 50-60 DEG C of stirring reaction 12 hours under argon shield, after reaction terminates, and filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression steam desolventize and excessive chloromethyl methyl ether, resistates through column chromatography purification (elutriant: chloroform-methanol=30:1 v/v), simultaneously 4 '-position protected by methoxy methylene radical trans-resveratrol (
5) and 3-position protected by methoxy methylene radical trans-resveratrol (
6), yield is respectively 46% and 28%, the equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.
By the trans-resveratrol of methoxy methylene radical obtained above protection (
5) or (
6) 2.0 mmol,
n,N-dimethyl formamide 20 ml, dibromo alkylate (
2) 8.0 mmol and 5.0 mmol salt of wormwood add in reaction flask, are warming up to 60-65 DEG C of stirring reaction 6.0 ~ 12.0 hours (reaction process TLC follows the tracks of) under argon shield; After reaction terminates, filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression is steamed and is desolventized and excessive dibromo alkylate, and resistates, through column chromatography purification (elutriant: chloroform-methanol=50:1 v/v), obtains accordingly 3,5-bis-replaces or 5,4 '-dibasic toluylene oxyalkyl bromine compounds (
7), yield 68%-88%.
Corresponding dibasic toluylene oxyalkyl bromine compounds of preparing above-mentioned (
7) 1.0 mmol are dissolved in 15 ml ethanol, add 4.0 mmol organic amine compounds (
4), temperature rising reflux stirring reaction 3.0 ~ 10.0 hours (reaction process TLC follows the tracks of) under argon shield; After reaction terminates; remove solvent under reduced pressure; 50 ml methylene dichloride are added in resistates; use 15 ml 5% aqueous sodium carbonates and 15 ml deionized water wash successively; organic layer filters after anhydrous sodium sulfate drying; remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: methylene dichloride), obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
8), yield 80%-96%.
By above-mentioned gained compound
8full dose adds in the mixing solutions of 10 ml 10% aqueous hydrochloric acids and 20 ml ethanol, stirring at room temperature reaction 3.0 ~ 8.0 hours (reaction process TLC follows the tracks of), after reaction terminates, remove solvent under reduced pressure, 50 ml methylene dichloride are added in resistates, use 20 ml 5% sodium bicarbonate aqueous solutions and 20 ml deionized water wash successively, organic layer filters after anhydrous sodium sulfate drying, remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: petroleum ether-ethyl acetate=30:1 v/v), obtain corresponding trans-resveratrol dialkylamine compounds (
i), yield 78%-97%, the equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
(continuous upper table)
(continuous upper table)
embodiment 4 is worked as
represent
, when Ar represents structural unit (A) or (B), method is led in the preparation of toluylene oxyalkyl amine based compound (I)
Add in reaction flask the corresponding toluylene phenolic compound of 2.0 mmol (
1),
n,N-dimethyl formamide 15 ml, 1-replacement-4-chlorine alkylpiperazine (
9) 5.0 mmol and 2.1 mmol salt of wormwood, under argon shield, be warming up to 70-80 DEG C of stirring reaction 6.0 ~ 18.0 hours (reaction process TLC follows the tracks of); After reaction terminates, filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression steam desolventize, resistates through column chromatography purification (elutriant: chloroform-methanol=30:1 v/v), obtain corresponding toluylene oxyalkyl amine based compound (
i).According to starting raw material toluylene phenolic compound used (
1) difference, can obtain toluylene oxyalkyl amine based compound that corresponding 3-position or 4 '-position replace (
i); Wherein, when toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
a) time, obtain 4 '-position replace toluylene oxyalkyl amine based compound (
i), yield 73%-87%; When toluylene phenolic compound (
1) Ar be R
3do not represent H structural unit (
b) time, obtain 3-position replace toluylene oxyalkyl amine based compound (
i), yield 60%-84%; When toluylene phenolic compound (
1) be trans-resveratrol (R
3represent H structural unit (
a) or (
b)) time, can obtain simultaneously 3-position replace toluylene oxyalkyl amine based compound (
i) and 4 '-position replace toluylene oxyalkyl amine based compound (
i), yield is respectively 15%-35% and 30%-49%.The equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
(continuous upper table)
embodiment 5 is worked as
represent
, Ar represents R
3
when not being structural unit (C) or (D) of H, method is led in the preparation of toluylene oxyalkyl amine based compound (I)
Add in reaction flask the corresponding toluylene phenolic compound of 2.0 mmol (
1),
n,N-dimethyl formamide 30 ml, 1-replacement-4-chlorine alkylpiperazine (
9) 10.0 mmol and 10.0 mmol salt of wormwood, under argon shield, be warming up to 80-85 DEG C of stirring reaction 5.0 ~ 16.0 hours (reaction process TLC follows the tracks of); After reaction terminates, filtered while hot, on a small quantity
n,N-dimethyl formamide washing leaching cake, filtrate decompression steam desolventize, resistates through column chromatography purification (elutriant: chloroform-methanol=50:1 v/v), obtain corresponding toluylene oxyalkyl amine based compound (
i).Wherein, when toluylene phenolic compound (
1) Ar be R
3represent CH
3structural unit (
c) time, obtain 3,4 '-dibasic toluylene oxyalkyl amine based compound (
i), yield 82%-93%; When toluylene phenolic compound (
1) Ar be R
3represent CH
3structural unit (
d) time, obtain the dibasic toluylene oxyalkyl amine based compound of 3,5-(
i), yield 70%-86%.The equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
embodiment 6 is worked as
represent
, Ar represents R
3
when the structural unit (C) of=H or (D), method is led in the preparation of toluylene oxyalkyl amine based compound (I)
2.0 mmol are added according to embodiment in reaction flask
3the trans-resveratrol of preparation-obtained methoxy methylene radical protection (
5) or (
6),
n,N-dimethyl formamide 25 ml, 1-replacement-4-chlorine alkylpiperazine (
9) 6.0 mmol and 6.0 mmol salt of wormwood, under argon shield, be warming up to 80-85 DEG C of stirring reaction 5.0 ~ 16.0 hours (reaction process TLC follows the tracks of); After reaction terminates; remove solvent under reduced pressure; 50 ml methylene dichloride are added in resistates; use 15 ml 5% aqueous sodium carbonates and 15 ml deionized water wash successively; organic layer filters after anhydrous sodium sulfate drying; remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: methylene dichloride), obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
10), yield 76%-95%.
By above-mentioned gained compound
10full dose adds in the mixing solutions of 10 ml 10% aqueous hydrochloric acids and 20 ml ethanol, stirring at room temperature reaction 3.0 ~ 8.0 hours (reaction process TLC follows the tracks of), after reaction terminates, remove solvent under reduced pressure, 50 ml methylene dichloride are added in resistates, use 20 ml 5% sodium bicarbonate aqueous solutions and 20 ml deionized water wash successively, organic layer filters after anhydrous sodium sulfate drying, remove solvent under reduced pressure, resistates through column chromatography purification (elutriant: petroleum ether-ethyl acetate=30:1 v/v), obtain corresponding trans-resveratrol dialkylamine compounds (
i), yield 70%-93%, the equal warp of its chemical structure
1h-NMR,
13c-NMR and ESI-MS confirms.The target compound structure adopting above-mentioned logical method to prepare is as follows:
ar represents
logical method prepared by embodiment 7 aryloxyalkyl group aminated compounds (I) and sour salify
Add in reaction flask according to above-described embodiment 1-6 gained toluylene oxyalkyl amine based compound (
i) 2.0 mmol and acetone 50 ml, it is sour accordingly to add 6.0 mmol after stirring, temperature rising reflux stirring reaction 20 minutes, be cooled to room temperature after reaction terminates, remove solvent under reduced pressure, resistates acetone recrystallization, filter separate out solid, obtain toluylene oxyalkyl amine based compound (
i) salt, its chemical structure warp
1h NMR and ESI-MS confirms.
Claims (8)
1. a class toluylene oxyalkyl amine based compound or its pharmacy acceptable salt, it is characterized in that the chemical structure of general formula of this compounds as (
i) shown in:
In formula:
arbe expressed as follows shown
(B)~
(D)middle any structural unit, n=1,2;
；
R
1represent H, C
1~ C
12alkyl; R
2represent C
1~ C
12alkyl, benzyl, substituted benzyl, 1,2,3,4-tetrahydro acridine-9-base, chloro-1,2,3, the 4-tetrahydro acridine-9-base of 6-, chloro-1,2,3, the 4-tetrahydro acridine-9-base of 8-or chloro-1,2,3, the 4-tetrahydro acridine-9-base of 6,8-bis-;
r 1 nR 2 also represent Pyrrolidine base, morpholinyl,
n-demethylgalanthamine base, piperidyl, 4-position are by C
1~ C
12the piperidyl that alkyl replaces, 4-position by benzyl or substituted benzyl replace piperidyl, piperazinyl, 4-position is by C
1~ C
12the piperazinyl that alkyl replaces, 4-position by benzyl or substituted benzyl the piperazinyl that replaces; R
3represent H, C
1~ C
12alkyl;
linkerrepresent (CH
2)
m, m represents 2-12; "
-O-Linker-NR 1 r 2 " also can be
, m represents 1-12, R
5represent H, C
1~ C
12alkyl, benzyl or substituted benzyl; Above-mentioned term " substituted benzyl " refer to by phenyl ring by 1-4 to be selected from the group of lower group the benzyl that replaces: F, Cl, Br, I, C
1-4alkyl, C
1-4alkoxyl group, trifluoromethyl, trifluoromethoxy, nitro, cyano group, these substituting groups can at any possible position of phenyl ring.
2. toluylene oxyalkyl amine based compound as claimed in claim 1 (
i) or its pharmacy acceptable salt, it is characterized in that described pharmacy acceptable salt is this type of toluylene oxyalkyl amine based compound and hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid, C
1-6aliphatic carboxylic acid, oxalic acid, phenylformic acid, Whitfield's ointment, toxilic acid, fumaric acid, succsinic acid, tartrate, citric acid, C
1-6the salt that alkylsulphonic acid, camphorsulfonic acid, Phenylsulfonic acid or tosic acid are formed.
3. as described in any one of claim 1-2 toluylene oxyalkyl amine based compound (
i) or the preparation method of its pharmacy acceptable salt, it is characterized in that the structural unit that the preparation method of described compound represents according to Ar and Linker or-O-Linker-NR
1r
2represent substituent difference, have following four kinds of methods:
method one: when Linker represents (CH
2
)
m
, Ar represents structural unit (B), and R
3
when not representing structural unit (C) and (D) of H:
In formula:
xrepresent Cl, Br, I; Ar, R
1, R
2, the definition of m, n and chemical structure of general formula (
i) identical;
With corresponding toluylene phenolic compound (
1) be starting raw material, in the basic conditions with Dihaloalkyl compound (
2) reaction, generate corresponding toluylene oxyalkyl halogen compound (
3), gained intermediate
3with organic amine compound (
4) react in a solvent, obtain corresponding toluylene oxyalkyl amine based compound (
i);
method two: when Linker represents (CH
2
)
m
, Ar is R
3
when the structural unit (C) of=H or (D)
In formula:
xrepresent Cl, Br, I; Ar, R
1, R
2, the definition of m and chemical structure of general formula (
i) identical;
With trans-resveratrol (
1) be starting raw material, react with chloromethyl methyl ether under solvent and alkaline condition, generate corresponding methoxy methylene radical protection trans-resveratrol (
5) or (
6), gained intermediate (
5) or (
6) under solvent and alkaline condition with Dihaloalkyl compound (
2) reaction, generate corresponding fragrant oxygen dialkyl group halogen compound (
7), this intermediate
7with organic amine compound (
4) react in a solvent, obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
8), compound
8under solvent and acidic conditions, remove methoxy methylene radical protecting group, obtain corresponding trans-resveratrol dialkylamine compounds (
i);
method three: when
represent
, Ar represents structural unit (B), and R
3
when not representing structural unit (C) and (D) of H:
In formula: X represents Cl, Br, I; Ar, R
5, the definition of m, n and chemical structure of general formula (
i) identical;
With corresponding toluylene phenolic compound (
1) be starting raw material, replace with 1-in the basic conditions-4-alkylhalide group piperazine (
9) reaction, obtain corresponding toluylene oxyalkyl amine based compound (
i);
method four: when
represent
, Ar is R
3
when the structural unit (C) of=H or (D):
In formula: X represents Cl, Br, I; Ar, R
5, the definition of m and chemical structure of general formula (
i) identical;
With methoxy methylene radical protection trans-resveratrol (
5) or (
6) be starting raw material, replace with 1-under solvent and alkaline condition-4-alkylhalide group piperazine (
9) reaction, obtain corresponding methoxy methylene radical protection trans-resveratrol dialkylamine compounds (
10), compound
10under solvent and acidic conditions, remove methoxy methylene radical protecting group, obtain corresponding trans-resveratrol dialkylamine compounds (
i);
Utilize above-mentioned four kinds of method gained toluylene oxyalkyl amine based compound (
i) in molecule containing amino, this amino, in alkalescence, can obtain acceptable salt on its pharmacology with any suitable acid by the salifying method of pharmaceutically routine.
4. the preparation method of toluylene oxyalkyl amine based compound or its pharmacy acceptable salt as claimed in claim 3, is characterized in that the step of method one
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine or TBAH; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane; Toluylene phenolic compound (
1): Dihaloalkyl compound (
2): the molar feed ratio of alkali is 1.0:1.0 ~ 15.0:1.0 ~ 15.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour;
The step of method one
b)in, reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile, C
1-8alcohol or C
5-8alkane; Compound (
3): organic amine compound (
4) molar feed ratio is 1.0:1.0 ~ 15.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour.
5. the preparation method of toluylene oxyalkyl amine based compound or its pharmacy acceptable salt as claimed in claim 3, is characterized in that the step of method two
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates or C
1-8an alkali metal salt of alcohol; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane; Trans-resveratrol (
1): chloromethyl methyl ether: the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 5.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 0.5 ~ 24 hour;
The step of method two
b)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine or TBAH; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane; Intermediate (
5) or (
6): Dihaloalkyl compound (
2): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour;
The step of method two
c)in, reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile, C
1-8alcohol or C
5-8alkane; Intermediate (
7): organic amine compound (
4) molar feed ratio be 1.0:1.0 ~ 10.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour;
The step of method two
d)in, reaction solvent for use is: water, C
1-6fatty alcohol,
n,N-dimethyl formamide, tetrahydrofuran (THF), C
3-8aliphatic ketone, acetonitrile, Isosorbide-5-Nitrae-dioxane or dimethyl sulfoxide (DMSO); Acid used is: hydrogenchloride, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phenylformic acid, C
1-6lipid acid, C
1-6alkylsulphonic acid, Phenylsulfonic acid, tosic acid or trifluoroacetic acid; The massfraction of acid in reaction system is 0.1%-100%, and temperature of reaction is 0 ~ 150 DEG C; Reaction times is 30 minutes ~ 24 hours.
6. the preparation method of toluylene oxyalkyl amine based compound or its pharmacy acceptable salt as claimed in claim 3, it is characterized in that in method three, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine or TBAH; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane; Toluylene phenolic compound (
1): 1-replacement-4-alkylhalide group piperazine (
9): the molar feed ratio of alkali is 1.0:1.0 ~ 15.0:1.0 ~ 15.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour.
7. the preparation method of toluylene oxyalkyl amine based compound or its pharmacy acceptable salt as claimed in claim 3, is characterized in that the step of method four
a)in, reacting alkali used is: alkali metal hydroxide, alkaline earth metal hydroxides, alkaline carbonate, alkaline earth metal carbonate, alkali metal hydrocarbonate, alkali metal bicarbonates, C
1-8an alkali metal salt of alcohol, triethylamine, Tributylamine, trioctylamine, pyridine,
n-methylmorpholine,
n-methyl piperidine, triethylene diamine or TBAH; Reaction solvent for use is: ether, tetrahydrofuran (THF),
n,N-dimethyl formamide, dimethyl sulfoxide (DMSO), methylene dichloride, chloroform, C
3-8aliphatic ketone, benzene, toluene, acetonitrile or C
5-8alkane; Methoxy methylene radical protection trans-resveratrol (
5) or (
6): 1-replacement-4-alkylhalide group piperazine (
9): the molar feed ratio of alkali is 1.0:1.0 ~ 10.0:1.0 ~ 10.0; Temperature of reaction is room temperature ~ 150 DEG C; Reaction times is 1 ~ 72 hour;
The step of method four
b)in, reaction solvent for use is: water, C
1-6fatty alcohol,
n,N-dimethyl formamide, tetrahydrofuran (THF), C
3-8aliphatic ketone, acetonitrile, Isosorbide-5-Nitrae-dioxane or dimethyl sulfoxide (DMSO); Acid used is: hydrogenchloride, hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phenylformic acid, C
1-6lipid acid, C
1-6alkylsulphonic acid, Phenylsulfonic acid, tosic acid or trifluoroacetic acid; The massfraction of acid in reaction system is 0.1%-100%; Temperature of reaction is 0 ~ 150 DEG C; Reaction times is 30 minutes ~ 24 hours.
8. the toluylene oxyalkyl amine based compound as described in any one of claim 1-2 or its pharmacy acceptable salt are preparing the purposes treated and/or prevented in nervus retrogression relative disease medicine, and this kind of nervus retrogression relative disease is: vascular dementia, Alzheimer's disease, parkinsonism, huntington disease, HIV related dementia disorders, multiple sclerosis, progressive lateral sclerosis disease, neuropathic pain or glaucoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310054592.0A CN103073440B (en) | 2013-02-21 | 2013-02-21 | Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310054592.0A CN103073440B (en) | 2013-02-21 | 2013-02-21 | Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103073440A CN103073440A (en) | 2013-05-01 |
| CN103073440B true CN103073440B (en) | 2015-06-03 |
Family
ID=48150163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310054592.0A Expired - Fee Related CN103073440B (en) | 2013-02-21 | 2013-02-21 | Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103073440B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201416273D0 (en) * | 2014-09-15 | 2014-10-29 | Isis Innovation | Therapeutic compounds |
| CN105439876B (en) * | 2014-09-19 | 2017-11-07 | 四川大学 | 2 hydroxylated chalcone aminated compounds, preparation method and use |
| CN105801448B (en) * | 2016-04-01 | 2017-11-14 | 南阳师范学院 | A kind of methoxy cinnamic acid benzamides compound of 4 amine alkoxy 3, preparation method and its usage |
| CN111065619B (en) * | 2017-08-29 | 2022-08-12 | 浙江海正药业股份有限公司 | (E) -alpha, beta-unsaturated amide compound, preparation method and application thereof |
| CN115850245B (en) * | 2022-12-30 | 2024-07-05 | 香港科技大学 | Stilbene compound, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5731662A (en) * | 1980-07-30 | 1982-02-20 | Mitsubishi Chem Ind Ltd | 4- 3-substituted piperidino butoxystilbene and its acid addition salt |
| WO2004000302A1 (en) * | 2002-06-25 | 2003-12-31 | Raju Gokaraju Ganga | Novel resveratrol analogs |
| CN1948274A (en) * | 2006-10-25 | 2007-04-18 | 沈阳药科大学 | Verakanol derivative, its preparation method and use |
| WO2010046926A2 (en) * | 2008-10-17 | 2010-04-29 | Aptuit Laurus Pvt Ltd | Novel stilbene analogs |
-
2013
- 2013-02-21 CN CN201310054592.0A patent/CN103073440B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5731662A (en) * | 1980-07-30 | 1982-02-20 | Mitsubishi Chem Ind Ltd | 4- 3-substituted piperidino butoxystilbene and its acid addition salt |
| WO2004000302A1 (en) * | 2002-06-25 | 2003-12-31 | Raju Gokaraju Ganga | Novel resveratrol analogs |
| CN1948274A (en) * | 2006-10-25 | 2007-04-18 | 沈阳药科大学 | Verakanol derivative, its preparation method and use |
| WO2010046926A2 (en) * | 2008-10-17 | 2010-04-29 | Aptuit Laurus Pvt Ltd | Novel stilbene analogs |
Non-Patent Citations (1)
| Title |
|---|
| 白藜芦醇衍生物及类似物的研究进展;陈国良等;《药学进展》;20060428;第30卷(第04期);145-150 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103073440A (en) | 2013-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103113340B (en) | One class Genistein alkyl amine compound, Preparation Method And The Use | |
| CN103087024B (en) | Flavone alkylamine compounds as well as preparation method and application thereof | |
| CN103073440B (en) | Diphenylvinyloxy alkylamine compound and preparation method as well as application thereof | |
| CN109651321B (en) | apigenin-O-alkylamine compound, preparation method and application | |
| CN109265451A (en) | Butyrylcholinesterasselective selective inhibitors and preparation method thereof and purposes | |
| CN105601540B (en) | A kind of methoxy cinnamic acid benzamides compound of 4 carbamate 3 and its production and use | |
| CN105622488A (en) | 4-cycloaminoalkoxy-3-methoxycinnamates, and preparation method and application thereof | |
| CN109824637A (en) | A kind of indone chalcone carbamate compound and its preparation method and application | |
| CN109793765A (en) | Application of the Ramulus et Folium Picrasmae in preparation prevention and treatment neurodegenerative disease drug or health care product | |
| CN108586411A (en) | A kind of naringenin carbamate compound, preparation method and application | |
| CN106749188B (en) | A kind of N- (benzyl piepridine base)-asafoetide amide-O- alkyl amine compound, preparation method and its usage | |
| CN105732479B (en) | A kind of 4- cyclammonium alkoxy -3- methoxy cinnamic acid benzamides compound, preparation method and its usage | |
| CN108586335B (en) | 2-hydroxybenzamide-1, 2,3, 4-tetrahydroisoquinoline-O-carbamate compound and preparation method thereof | |
| CN105801448B (en) | A kind of methoxy cinnamic acid benzamides compound of 4 amine alkoxy 3, preparation method and its usage | |
| CN105646289B (en) | A kind of 4- carbamates -3- methoxycinnamate acid amide alkylamide compounds and its preparation method and application | |
| CN113185447B (en) | Phthaloyl cysteamine compound, preparation method and application thereof | |
| CN108024990A (en) | Conjugate of Memantine and arctigenin and combinations thereof and purposes | |
| CN110272349B (en) | 2' -hydroxy-3-phenyl propiophenone compound and preparation method and application thereof | |
| CN106748969A (en) | A kind of N (4 benzyl piepridine base) asafoetide amide compound, preparation method and its usage | |
| CN109665969B (en) | 3-methoxy-4-hydroxychalcone bis-Mannich base compound, and preparation method and application thereof | |
| CN109761883B (en) | 4-carbamate-cinnamamide-4-benzyl piperidine compound and preparation method and application thereof | |
| CN109678795A (en) | 4- carbamate-asafoetide amide -1,2,3,4- tetrahydroisoquinolicompounds compounds and its preparation method and application | |
| CN109666013B (en) | Bipiperidine substituted isoflavone compound and use thereof | |
| CN106798743B (en) | Purposes of (N- the isopropyl piperazinyl) -2-Hydroxylbenzamide compound in preparation treatment neurodegenerative disease drug | |
| CN108299367A (en) | A kind of celery aglycon carbamate compound, preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150603 Termination date: 20190221 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |